Haprolid Inhibits Tumor Growth of Hepatocellular Carcinoma through Rb/E2F and Akt/mTOR Inhibition.

Thumbnail
Name:
Xing et al.pdf
Size:
3.837Mb
Format:
PDF
Description:
Open Access publication
Download
Cast your vote
 
Your vote was cast
Thank you for your feedback
Authors
Xing, Jun
Bhuria, Vikas
Bui, Khac Cuong
Nguyen, Mai Ly Thi
Hu, Zexi
Hsieh, Chih-Jen
Wittstein, Kathrin
Stadler, Marc cc
Wilkens, Ludwig
Li, Jun
Issue Date
2020-03-06

Metadata
Show full item record
Abstract
The efficacy of haprolid was evaluated in human HCC cell lines (Huh-7, Hep3B and HepG2) and xenograft tumors (NMRI-Foxn1nu mice with injection of Hep3B cells). Cytotoxic activity of haprolid was determined by the WST-1 and crystal violet assay. Wound healing, transwell and tumorsphere assays were performed to investigate migration and invasion of HCC cells. Apoptosis and cell-cycle distribution were measured by flow cytometry. The effects of haprolid on the Rb/E2F and Akt/mTOR pathway were examined by immunoblotting and immunohistochemistry.
Citation
Cancers (Basel). 2020 Mar 6;12(3). pii: cancers12030615. doi: 10.3390/cancers12030615.
Affiliation
HZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.
Publisher
MDPI
Journal
Cancers
URI
http://hdl.handle.net/10033/622214
DOI
10.3390/cancers12030615
PubMed ID
32155915
Type
Article
Language
en
ISSN
2072-6694
Collections

The following license files are associated with this item:

  • Creative Commons
Attribution-NonCommercial-ShareAlike 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International